Houston organizations identify promising life science cos. at annual event

startups to watch

The Rice Alliance and BioHouston acknowledged innovations from a dozen promising health tech companies. Photo via Rice University

For the 13th year, the Texas Life Science Forum hosted by BioHouston and the Rice Alliance for Technology and Entrepreneurship celebrated innovative companies from around the world that are creating new treatments and solutions to today's biggest health care challenges.

This week, over 40 companies presenting their innovations across cancer, cardiovascular disease, biotechnology, and more. Nearly 700 venture capitalists, corporate innovation groups, angel networks, industry leaders, academics, service providers, and others attended the event on November 7 at Rice's BioScience Research Collaborative in the Texas Medical Center.

Just like in previous years, the event ended with the announcement of the 10 companies that were deemed "most promising" based on their pitches and technologies. Of the 10 companies named, six are headquartered in Houston and an additional two startups on the list have a presence here.

The 2024 most-promising life science companies are:

Houston-based clinical-stage cell therapy company March Biosciencesis developing a pipeline of innovative therapies, beginning with targeting relapsed an refractory T cell lymphoma.

ImmunoGenesis, headquartered in Houston, is a clinical-stage biotechnology company developing a potent PD-1 pathway targeting agent specifically engineered for immuneexcluded tumors, which account for over 50 percent of all cancers

Taurus Vascular, based in Houston, is revolutionizing endovascular aneurysm repair by addressing the critical issues of residual aneurysm pressurization and endoleaks with its catheter-deployable aortocaval shunt.

Headquartered in Australia with a Houston presence, Foxo Technologyoffers HIPAA-compliant, communication software for anyone in health care.

Another Houston company,Voythoshas built an AI platform to better predict and diagnose cardiovascular disease earlier to enhance quality and cost of care.

Dutch company Loop Robot, which has a presence in Houston, automates disinfection with its intelligent robot to make medical-grade disinfection faster, safer, and digitally auditable.

London-based Case45develops and commercializes pan-cancer prognostic tests using unique integration of tumor evolution and AI and is beginning with breast and lung cancers.

OmniNano Pharmaceuticals, headquartered in Houston, has developed a nano-drug delivery platform technology enables simultaneous co-delivery of multiple therapeutic agents designed specifically to treat solid tumors.

Houston-based clinical-stage biopharmaceutical company Mongoose Bio is pioneering first-in-class T cell receptor T cell (TCR-T) therapies for cancer treatment.

Rua Diagnosticsfrom New York is redefining point-of-care diagnostics with advanced micro gas chromatography technology for breath analysis that's capable of detecting a wide range of prevalent and deadly diseases.

In addition to this list, the event named two additional awards. United Kingdom's Cytecom, which provides quick and accurate diagnosis and treatment of blood infections stems, was selected by the crowd as the People's Choice award winner.

Last, but not least, BioHouston's Ann Tanabe awarded this year's Michael E. Debakey Award to Houston-based Autoimmunity BioSolutions, seed-stage biotech developing a next-generation, immuno-corrective therapy for treatment of autoimmune diseases to restore normal immune function.

From Your Site Articles
Four Houston startups have received over $40 million in funding from a Texas organization. Photo via Getty Images

4 Houston life science startups secure over $40M in CPRIT funding

cha-ching

Four Houston bioscience startups have collected nearly $43 million in grants from the Cancer Prevention and Research Institute of Texas (CPRIT).

Here’s a list of the four startups, the amount and purpose of each grant, and some background information about each company.

Stingray Therapeutics

CPRIT grant amount: $13,881,458

Purpose of grant: Clinical trial to evaluate an immunotherapy known as SR-8541A for treatment of advanced or metastatic solid tumors.

Company background: Stingray received a $2 million Small Business Innovation Research (SBIR) award in 2022. In conjunction with the award, Mohan Kaadige, a research associate professor at the Translational Genomics Research Institute, joined Stringray as the principal SR-8541A investigator.

“I … believe we have great potential to alleviate cancer suffering in the near future with this exciting technology,” says Kaadige.

March Biosciences

CPRIT grant amount: $13,358,637

Purpose of grant: Clinical trial to evaluate a T-cell immunotherapy (MB-105) for treatment of certain types of relapsed lymphoma.

Company background: March Biosciences, a Baylor College of Medicine spinout, recently received $4.8 million in funding from Cancer Focus Fund, affiliated with Houston’s MD Anderson Cancer Center.

“The breadth and quality of the support we are receiving from our local partners and institutions underscore Houston’s increasing prominence as a worldwide leader in cancer R&D and clinical research,” says Sarah Hein, co-founder and CEO of March Biosciences.

Mongoose Bio

CPRIT grant amount: $10,621,053

Purpose of grant: Development of T-cell therapies targeting solid-tumor cancer.

Company background: Mongoose founder Cassian Lee, a professor and researcher at MD Anderson, is a CPRIT scholar and a participant in Texas Medical Center Innovation’s 2023 Accelerator for Cancer Therapeutics.

“Mongoose Bio is a first-rate example of the use of CPRIT funds to fund a disruptive cell gene therapy … therapeutic with deep roots and origins in Texas. This innovation will benefit patients with solid tumors not just in Texas but the rest of the world,” says CPRIT.

FixNip

CPRIT grant amount: $4,844,088

Purpose of grant: Clinical study and manufacturing of a silicone implant that creates a soft, natural-looking nipple for women with breast cancer who’ve undergone post-mastectomy breast reconstruction. The clinical study will be done at MD Anderson.

Company background: In conjunction with the CPRIT grant, FixNip is moving its headquarters from Israel to Houston. Austin-based CPRIT became aware of FixNip during a May 2022 trade trip to Israel by the organization’s CEO, Wayne Roberts.

“Loss of nipple projection is the most pervasive problem across all currently existing nipple reconstruction solutions,” says FixNip.

Aside from the grants for the four Houston startups, CPRIT handed out two grants for recruitment of two cancer researchers to Houston:

  • $6 million grant to recruit Dr. Leonido Luznik of Johns Hopkins University to the Baylor College of Medicine. Luznik’s research focuses on allogeneic blood and marrow transplantation (alloBMT), a treatment for blood cancers.
  • $1.99 million grant to recruit Swiss researcher Christina Tringides to Rice University. Tringides is working on a “groundbreaking” treatment for brain tumors, says CPRIT.
This year, seven of the 10 most-promising life science companies are based in Houston. Photo courtesy of Rice Alliance

Houston startups dominate ‘most-promising’ companies announcement at annual event

on the list

Rice University played host this week to the 12th annual Texas Life Science Forum, where life science leaders and startup founders could network, learn and present pitches on their solutions to a wide array of health-related issues.

Hosted by Rice Alliance for Technology and Entrepreneurship and BioHouston on November 7, the event brought together more than 600 attendees for a series of keynote speakers and panels. This year, 45 early-stage therapeutic, diagnostic, medical device and digital health companies—many of which are based in Houston—also pitched their concepts.

Fort Worth-based AyuVis Research walked away from the event with the two top recognitions: The Michael E. DeBakey Memorial Life Science Award and the People's Choice Award. The company, which has developed a small molecule immunotherapy targeting bronchopulmonary dysplasia (BPD) in preterm neonates and other respiratory disorders. The company is raising a $20 million Series A round to support its clinical development and is slated to pitch at IGNITE Health’s Fire Pitch 2023 today, November 9, at the Ion.

Each year the Rice Alliance and BioHouston also name its 10 most promising life science companies, selected by investors—seven out of 10 of which are based in Houston. This year's selection included the following companies, in alphabetical order:

  • 7 Hills Pharma: This Houston-based clinical stage immunotherapy company has developed the concept of allosteric activation of integrins to facilitate cell adhesion and promote immune responses. The concept has uses in preventing infection and cancer, and increasing the effectiveness of oncology drugs and infectious disease vaccines.
  • Bairitone Health: This Houston-based company is building a scalable diagnostic system for sleep apnea anatomy utilizing home-use wearable, passive Sonar technology and AI techniques.
  • Diakonos Oncology: Also based in Houston, Diakonos' Dendritic Cell Vaccine was awarded the FDA’s Fast Track designation. The clinical-stage biotech company's immunotherapies have shown early successes for hard-to-reach, aggressive cancers like Glioblastoma Multiforme.
  • Mongoose Bio: With more than 20 years of research, Mongoose specializes in T cell-based therapies for diverse solid tumors TCR-based therapies in cancer patients. The Houston-based company has developed an immunopeptidome discovery platform for TCR-based therapies in cancer patients.
  • Nandi Life Sciences: Nandi is developing antibodies for Avastin-resistant ovarian cancer, with
  • further application in breast, colorectal and lung cancer. The company is based out of Texas Medical Center Innovation.
  • NKILT Therapeutics: This Houston-based company's seed-stage cell therapy has applications in solid tumors, such as colorectal cancer, ovarian cancer, clear cell renal carcinoma, endometrial
  • cancer and more. It is developing a novel and proprietary Chimeric ILT-Receptor.
  • NuVision Biotherapies: Based in the United Kingdom, NuVision has developed and proven a treatment for dry eye disease. It's known for its Omnigen and OmniLenz products and is raising a series A to scale, take the business to profitability and exit.
  • Panakeia Technologies: Also based in the UK, Panakeia has developed an AI-based software that can provide multi-omic biomarkers in minutes. Currently this process takes days or weeks. It's RuO platform can identify 4,500 known multi-omics cancer markers.
  • Taurus Vascular: A recent spin-out of the Texas Medical Center Innovation Biodesign program, Taurus is developing a novel, catheter-based solution for treating endoleaks, which can be related to aortic aneurysms.
  • YAP Therapeutics: The only California-based company to make the cut, this preclinical-stage biotech develops genetic medicines that leverage the company’s tissue renewal and regeneration platform to reverse and cure severe diseases, including heart failure, pulmonary diseases, retinal degeneration and hearing loss.

Last year, Bairitone Health took home the DeBakey and People's Choice awards.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

New energy innovation and coworking spaces open at the Ion

moving in

Houston-based Occidental officially opened its new Oxy Innovation Center with a ribbon cutting at the Ion last week.

The opening reflects Oxy and the Ion's "shared commitment to advancing technology and accelerating a lower-carbon future," according to an announcement from the Ion.

Oxy, which was named a corporate partner of the Ion in 2023, now has nearly 6,500 square feet on the fourth floor of the Ion. Rice University and the Rice Real Estate Company announced the lease of the additional space last year, along with agreements with Fathom Fund and Activate.

At the time, the leases brought the Ion's occupancy up to 90 percent.

Additionally, New York-based Industrious plans to launch its coworking space at the Ion on May 8. The company was tapped as the new operator of the Ion’s 86,000-square-foot coworking space in Midtown in January.

Dallas-based Common Desk previously operated the space, which was expanded by 50 percent in 2023 to 86,000 square feet.

CBRE agreed to acquire Industrious in a deal valued at $400 million earlier this year. Industrious also operates another local coworking space is at 1301 McKinney St.

Industrious will host a launch party celebrating the new location Thursday, May 8. Find more information here.


  

Oxy Innovation Center. Photo via LinkedIn.

Houston improves ranking among best U.S. cities to start a business

Business News

Houston's reputation for being an entrepreneurial and business powerhouse was confirmed in WalletHub's new list of the "Best Large Cities to Start a Business" in 2025. The Energy Capital of the World moved up four spots this year and ranked No. 34 nationwide.

The annual report ranked 100 U.S. cities based on 19 metrics across three main categories: business environment, access to resources, and costs. Factors considered in the report include five-year business survival rates, job growth comparisons from 2019 and 2023, office space affordability, and more.

The sunny Florida city of Orlando (No. 1) topped the list as the best large city for starting a business this year.

Houston's business climate has improved slightly since 2024, when the city previously ranked No. 38.

Houston performed the best in the national business environment category, ranking No. 33 out of all 100 cities in the report. It fell behind in the categories for "business costs" and "access to resources" ranking No. 50 and No. 65, respectively.

"Starting a business can be very scary, considering one in every five startups doesn’t make it past the first year," said WalletHub analyst Chip Lupo. "That’s why it’s especially important to live in a city that provides an environment where new businesses can thrive, with enough capital, workers and customers to keep it going long-term."

Elsewhere in Texas
Austin was the only Texas city to rank among the top 10 best big cities to start a business in 2025, climbing up into the No. 3 spot.

"Businesses that are currently in Austin are thriving, as the city has a very high growth rate in the number of small businesses," the report said. "It also has the best employment growth in the country, which makes it more likely that new businesses will be able to find employees."

Dallas-Fort Worth had the greatest concentration of cities on the list, contributing six out of 13 total Texas cities, and all of them among the top 50: Fort Worth (No. 11), Arlington (No. 15), Dallas (No. 16), Irving (No. 22), Garland (No. 29), and Plano (No. 43).

Other large Texas cities that were named among the best places to start a business in 2025 include Lubbock (No. 33), Laredo (No. 44), San Antonio (No. 64), El Paso (No. 67), and Corpus Christi (No. 70).

The top 10 best large cities to start a business in 2025 are:

  • No. 1 – Orlando, Florida
  • No. 2 – Tampa, Florida
  • No. 3 – Austin, Texas
  • No. 4 – Jacksonville, Florida
  • No. 5 – Miami, Florida
  • No. 6 – St. Petersburg, Florida
  • No. 7 – Boise, Idaho
  • No. 8 – Atlanta, Georgia
  • No. 9 – Raleigh, North Carolina
  • No. 10 – Hialeah, Florida
---

A version of this story originally appeared on our sister site, CultureMap.com.

Houston space tech leader lands up to $10 million for Earth re-entry vehicle and lab

space funding

Houston-based space technology, infrastructure, and services company Intuitive Machines has been awarded a state grant of up to $10 million to help develop an Earth re-entry vehicle and in-space biomanufacturing lab.

The Texas Space Commission approved the grant, which is coming from the state’s Space Exploration and Research Fund.

Intuitive Machines says the money will support its “critical risk-reduction platform” for returning lunar samples to Earth. The funding will go toward an early 12-month phase of the project.

“Returning samples from space is one of the most complex challenges in exploration,” says Tim Crain, chief growth officer at Intuitive Machines.

In 2022, Intuitive Machines began preliminary design work on an Earth re-entry vehicle for missions returning from low Earth orbit, the moon, or Mars. In tandem with development of the re-entry vehicle, the company has teamed up with Houston-based biotech company Rhodium Scientific on in-space biomanufacturing. This biomanufacturing will involve certain materials, processes and pharmaceuticals that can be handled more efficiently in space or that exhibit unique non-Earth properties.

Gámez Holzhaus, founder and CEO of Rhodium Scientific, says his company’s federally backed work “has enabled us to establish all hardware and protocols necessary for a pipeline to develop and scale biomanufacturing in space.”

Intuitive Machines and Rhodium Scientific say the state grant should pave the way for future grants and large-scale projects to bring the re-entry system closer to flight readiness.

View All Listings